文摘
|
Background Our previous studies have demonstrated potent oncolysis efficacy of the E1A, E1B double-restricted replication-competent oncolytic adenovirus AxdAdB-3 for treatment of bladder cancer. Here, we reported the feasibility and efficacy of AxdAdB-3 alone, or in combination with gemcitabine for treating renal cell carcinoma. Methods Cytopathic effects of AxdAdB-3 were evaluated in human renal cell carcinoma cell lines TOS-1, TOS-2, TOS-3, TOS-3LN, SMKT-R3, SMKT-R4 and ACHN, and in normal human renal proximal tubule epithelial cells (RPTEC). AxdAdB-3 induced down-regulation of the cell cycle was determined by flow cytometry. Combination therapies of AxdAdB-3 with gemcitabine were evaluated in vitro and in vivo on subcutaneous TOS-3LN tumors in a severe combined immunodeficiency disease (SCID) mouse model. Results AxdAdB-3 was potently cytopathic against the tested most renal cell carcinoma cell lines including TOS-2, TOS-3, TOS-3LN, SMKT-R3 and SMKT-R4, while normal human RPTEC were not destroyed. AxdAdB-3 effectively induced cell cycle S-phase entry. Combined therapy of AxdAdB-3 with gemcitabine demonstrated stronger antitumor effects in vitro and in vivo compared with either AxdAdB-3 or gemcitabine alone. Conclusion AxdAdB-3 alone, or in combination with gemcitabine may be a promising strategy against renal cell carcinoma. |
来源
|
Chinese Medical Journal
,2011,124(7):1082-1087 【核心库】
|
DOI
|
10.3760/cma.j.issn.0366-6999.2011.07.024
|
关键词
|
oncolysis
;
adenovirus
;
gemcitabine
;
renal cell carcinoma
|
地址
|
1.
Department of Urology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, 310022
2.
Department of Urology, Se-en Hospital, Japan, Japan, Tagajyo
3.
Department of Molecular Medicine, Sapporo Medical University, Japan, Japan, Sapporo
4.
Division of Urology, Chair of Surgery Tohoku University Graduate School of Medicine, Japan, Japan, Sendai
|
语种
|
英文 |
文献类型
|
研究性论文 |
ISSN
|
0366-6999 |
学科
|
外科学 |
基金
|
in part by the Qianjiang Program of Zhejiang Province
|
文献收藏号
|
CSCD:4428515
|